

## The Association of Brachial-Ankle Pulse Wave Velocity with Acute Postprandial Hyperglycemia in Korean Pre-diabetic and Diabetic Subjects

Chul Woo Ahn

Division of Endocrinology and Metabolism, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

Subjects with diabetes have accelerated atherosclerotic vascular lesions. The risk of having coronary, cerebral, and peripheral arterial diseases is higher in diabetic subjects than in non-diabetic subjects [1]. Atherosclerosis involves a combination of fatty degeneration and vessel stiffening of the arterial wall. Sclerotic changes are more difficult to assess than atherosclerosis and, because of this, it has attracted less attention. For example, the standard evaluation of atherosclerosis by histopathology and serial angiography is a sensitive method that does not detect sclerotic changes [2]. In animal studies, a direct relationship has been established between regression of atherosclerosis and an increase in arterial distensibility [3,4].

Pulse wave velocity (PWV) is known to be an indicator of arterial stiffness [5,6], and has been regarded as a marker of vascular damage [7,8]. Recent studies have demonstrated that PWV is not only a marker of vascular damages, but also a prognostic predictor when it is measured using noninvasive automatic devices [9,10]. Therefore, PWV can be potentially used for screening vascular damage in a large population [6,11]. Recently, an instrument was developed to measure brachial-ankle PWV (baPWV) by using a volume-rendering [12]. Nakamura et al. have found that the length of abdominal aorta that is affected by calcification, which is a known risk factor for cardiovascular morbidity and mortality, also independently

predicted baPWV [13]. Accordingly, baPWV could be used as a new measure of vascular damage that may predispose an individual to cardiovascular events. baPWV was mainly affected by age, systolic blood pressure and sex. Many other factors, such as body weight, body mass index (BMI), waist to hip ratio, HbA1c, microalbuminuria, triglyceride,  $\gamma$ -GTP, and duration of diabetes mellitus, also affected baPWV [14].

Long-term glycemic control is known to be correlated with the changes of baPWV in type 2 diabetic subjects who frequently have accompanying insulin resistance for 12 months [15]. In addition, hyperinsulinemia contributes to the development of arterial stiffness, which is assessed by measuring the baPWV, in the early stages of type 2 diabetes mellitus [16]. Glycemic control and the hyperinsulinemic state are important factors that determine the PWV in diabetic subjects. In a study of university students in Japan, baPWV was significantly higher in obese ( $BMI > 30 \text{ kg/m}^2$ ) male subjects than in the overweight ( $25 < BMI < 30 \text{ kg/m}^2$ ) subjects and higher in the males with nonalcoholic fatty liver disease (NAFLD) than in those without NAFLD [17].

In the present study, the investigators measured baPWV, fasting, 30- and 120-minute post-challenge glucose levels, as well as other metabolic parameters, in 633 subjects with fasting hyperglycemia. Among the participants, 62.9% were pre-

Corresponding author: Chul Woo Ahn  
Division of Endocrinology and Metabolism, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 612 Eonju-ro, Gangnam-gu, Seoul 135-270, Korea  
E-mail: acw@yuhs.ac

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

diabetic, and 31.7% were diagnosed with having diabetes. The mean baPWV value was significantly higher in subjects with diabetes, when compared with that of the pre-diabetic group. This was especially the case for the 30-minute post-challenge glucose level, which was a significant determinant for the mean baPWV value, even after the adjustment for other confounding variables. This finding corresponds to the results of a study by Succurro et al. [18] that had included 400 Caucasian subjects. Succurro et al. suggested that normal glucose tolerance subjects with a 1-hour post-load glucose  $\geq 155$  mg/dL have an atherogenic profile that includes having an intima-media thickness that is similar to impaired glucose tolerance subjects, which suggests that there is an association of post-challenge plasma glucose levels other than 2-hour glucose levels with the development of atherosclerosis and diabetes mellitus. Moreover, there is some evidence that post-challenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or the HbA1c level [19]. Therefore, postprandial hyperglycemia may be a good candidate for predicting future atherosclerosis and metabolic syndrome, and eventually cardiovascular disease in high-risk subjects.

In this study, the investigators provided valuable evidence of the relationship between the 30-minute post-challenge glucose level and the baPWV in Korean subjects with fasting hyperglycemia. Although the investigators did not include subjects with normoglycemia, the baPWV was significantly correlated with post-challenge 30-minute glucose levels during oral glucose tolerance test, more so than either the 120-minute or fasting glucose levels in subjects with hyperglycemia. The limitation of this study is the absence of the difference in mean baPWV between subjects with normoglycemia and hyperglycemia. As the author had stated, there was no patients with normoglycemia since study subjects were referred to the endocrinology department, due to the detection of a high fasting glucose level at least once. Therefore, it seems reasonable to compare the diabetic group to a control group. Despite this limitation, the importance of this study is that it focuses on the effect that acute hyperglycemic excursion has on arterial stiffness in subjects with glucose intolerance. Finally, I express my gratitude to the authors for conducting this study and fully expect of its expansion in order to yield even more useful results.

## REFERENCES

- Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population: sixteen year follow-up study. *Diabetes* 1974;23:105-11.
- Blankenhorn DH, Krams DM. Reversal of atherosclerosis and sclerosis: the two components of atherosclerosis. *Circulation* 1989;79:1-7.
- Farrar DJ, Green HD, Wagner WD, Bond MG. Reduction in pulse wave velocity and improvement of aortic distensibility accompanying regression of atherosclerosis in the rhesus monkey. *Circ Res* 1980;47:425-35.
- Taniwaki H, Kawagishi T, Emoto M, Shoji T, Kanda H, Maekawa K, Nishizawa Y, Morii H. Correlation between the intima-media thickness of the carotid artery and aortic pulse-wave velocity in subjects with type 2 diabetes: vessel wall properties in type 2 diabetes. *Diabetes Care* 1999;22:1851-7.
- Lehmann ED. Clinical value of aortic pulse-wave velocity measurement. *Lancet* 1999;354:528-9.
- Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brissac AM, Target R, Levy BI. Assessment of arterial distensibility by automatic pulse wave velocity measurement: validation and clinical application studies. *Hypertension* 1995;26:485-90.
- Cohn JN. Vascular wall function as a risk marker for cardiovascular disease. *J Hypertens Suppl* 1999;17:S41-4.
- van Popele NM, Grobbee DE, Bots ML, Asmar R, Topouchian J, Reneman RS, Hoeks AP, van der Kuip DA, Hofman A, Witteman JC. Association between arterial stiffness and atherosclerosis: the Rotterdam Study. *Stroke* 2001;32:454-60.
- Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. *Hypertension* 2001;37:1236-41.
- Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. *Circulation* 2001;103:987-92.
- Asmar R, Topouchian J, Pannier B, Benetos A, Safar M; Scientific, Quality Control, Coordination and Investigation Committees of the Complior Study. Pulse wave velocity as endpoint in large-scale intervention trial: the Complior study. *J Hypertens* 2001;19:813-8.
- Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, Koji Y, Hori S, Yamamoto Y. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. *Hypertens Res* 2002;25:359-64.
- Yun KW, Kim BH, Bae YP, Yi BD, Lee SW, Lim HK, Ryu YS, Lee CW. Determinants of 1-year changes of brachial ankle pulse wave velocity (baPWV) in subjects with type 2 diabetes

- mellitus. *Korean Diabetes J* 2008;32:346-57.
14. Nakamura U, Iwase M, Nohara S, Kanai H, Ichikawa K, Iida M. Usefulness of brachial-ankle pulse wave velocity measurement: correlation with abdominal aortic calcification. *Hypertens Res* 2003;26:163-7.
  15. Shimizu H, Shimomura K, Negishi M, Oh-I S, Tomita Y, Uehara Y, Mori M. Glycaemic control and the increase in pulse wave velocity (PWV) in type 2 diabetic patients. *Diabet Med* 2004;21:804-5.
  16. Koizumi M, Shimizu H, Shimomura K, Oh-I S, Tomita Y, Kudo T, Iizuka K, Mori M. Relationship between hyperinsulinemia and pulse wave velocity in moderately hyperglycemic patients. *Diabetes Res Clin Pract* 2003;62:17-21.
  17. Shiotani A, Motoyama M, Matsuda T, Miyanishi T. Brachial-ankle pulse wave velocity in Japanese university students. *Intern Med* 2005;44:696-701.
  18. Succurro E, Marini MA, Arturi F, Grembale A, Lugara M, Andreozzi F, Sciacqua A, Lauro R, Hribal ML, Perticone F, Sesti G. Elevated one-hour post-load plasma glucose levels identifies subjects with normal glucose tolerance but early carotid atherosclerosis. *Atherosclerosis* 2009;207:245-9.
  19. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. *Diabetes Care* 2000; 23:1830-4.